| |
Tamoxifen (n = 240)
|
Toremifene (n = 212)
|
|---|
|
Recurrences
|
23(9.6%)
|
6(2.8%) 2
|
|
Logoregional
|
14
| |
|
Distant
|
15
|
4
|
|
Lymph nodes or other soft tissues
|
3
|
2
|
|
Bone
|
8
|
2
|
|
Liver
|
4
|
1
|
|
Contralateral breast cancer
|
1
|
0
|
|
Brain
|
2
|
0
|
|
Lung
|
4
|
0
|
|
Deaths
|
5(2.1%)
|
0(0%)
|
|
Breast cancer
|
4
|
0
|
|
Other reasons
|
1
|
0
|
- In the tamoxifen group, there were 12 patients with multiple site of recurrence, of which 7 had more than one site where distant metastases were detected, 5 had concurrent locoregional and one or more sites of distant recurrence. In the toremifene group, there was 1 patient who had concomitant bone and liver metastases.
